AXSM
Price:
$87.11
Market Cap:
$4.18B
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective an...[Read more]
Industry
Biotechnology
IPO Date
2015-11-19
Stock Exchange
NASDAQ
Ticker
AXSM
According to Axsome Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -174.48%. This represents a change of 250.11% compared to the average of -49.83% of the last 4 quarters.
The mean historical ROE of Axsome Therapeutics, Inc. over the last ten years is 17.19%. The current -174.48% ROE has changed -1115.23% with respect to the historical average. Over the past ten years (40 quarters), AXSM's ROE was at its highest in in the March 2015 quarter at 66.83%. The ROE was at its lowest in in the September 2018 quarter at -1115.03%.
Average
17.19%
Median
37.80%
Minimum
-180.52%
Maximum
187.37%
Discovering the peaks and valleys of Axsome Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 75.36%
Maximum Annual ROE = 187.37%
Minimum Annual Increase = -647.39%
Minimum Annual ROE = -180.52%
Year | ROE | Change |
---|---|---|
2023 | -125.27% | -30.60% |
2022 | -180.52% | -647.39% |
2021 | 32.98% | -12.76% |
2020 | 37.80% | -4.59% |
2019 | 39.62% | 37.60% |
2018 | 28.79% | -23.82% |
2017 | 37.79% | -33.81% |
2016 | 57.10% | 1.59% |
2015 | 56.20% | -70.00% |
2014 | 187.37% | 75.36% |
The current ROE of Axsome Therapeutics, Inc. (AXSM) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-90.94%
5-year avg
-39.08%
10-year avg
17.19%
Axsome Therapeutics, Inc.’s ROE is less than Incyte Corporation (0.78%), greater than ImmunoGen, Inc. (-21.97%), less than Sarepta Therapeutics, Inc. (5.17%), less than ACADIA Pharmaceuticals Inc. (6.89%), greater than Viking Therapeutics, Inc. (-12.73%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), less than Seres Therapeutics, Inc. (313.56%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than TG Therapeutics, Inc. (-38.21%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), greater than Akero Therapeutics, Inc. (-29.56%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Blueprint Medicines Corporation (-47.66%), greater than PDS Biotechnology Corporation (-137.06%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%),
Company | ROE | Market cap |
---|---|---|
0.78% | $14.61B | |
-21.97% | $8.73B | |
5.17% | $11.79B | |
6.89% | $2.44B | |
-12.73% | $7.12B | |
-71.78% | $7.28B | |
313.56% | $138.56M | |
-78.24% | $794.69M | |
-38.21% | $3.74B | |
-39.58% | $594.85M | |
-328.66% | $3.68M | |
-29.56% | $2.24B | |
19.32% | $6.57B | |
-22.40% | $1.50B | |
-47.66% | $5.84B | |
-137.06% | $119.48M | |
-46.15% | $389.77M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Axsome Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Axsome Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Axsome Therapeutics, Inc.'s ROE?
How is the ROE calculated for Axsome Therapeutics, Inc. (AXSM)?
What is the highest ROE for Axsome Therapeutics, Inc. (AXSM)?
What is the 3-year average ROE for Axsome Therapeutics, Inc. (AXSM)?
What is the 5-year average ROE for Axsome Therapeutics, Inc. (AXSM)?
How does the current ROE for Axsome Therapeutics, Inc. (AXSM) compare to its historical average?